Exocrine Pancreatic Insufficiency is frequently an unrecognized consequence of benign and malignant pancreatic disease, leading to various consequences such as abdominal discomfort, steatorrhea, malnutrition, sarcopenia, osteoporosis, weight loss, reduced quality of life, and diminished survival.
Despite these rather severe outcomes, the diagnosis and management of Exocrine Pancreatic Insufficiency (EPI) are suboptimal, which underscores the importance of awareness in high-risk patients, appropriate use of diagnostic testing, and understanding of treatment goals and strategies. However, current literature suggests that patients who are at high risk of developing Exocrine Pancreatic Insufficiency (EPI) do not undergo testing or are not treated with adequate dosages.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/exocrine-pancreatic-insufficiency-epi-market
The Exocrine Pancreatic Insufficiency (EPI) market report also covers emerging drugs, current treatment practices, Exocrine Pancreatic Insufficiency (EPI) market share of the individual therapies, current and forecasted Exocrine Pancreatic Insufficiency (EPI) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Exocrine Pancreatic Insufficiency (EPI) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Exocrine Pancreatic Insufficiency (EPI) Market Key Facts
-
According to a study titled “Epidemiology of pancreatic diseases in Lunenburg County. A study in a defined German population” conducted by Lankisch PG et al., the estimated prevalence of Exocrine Pancreatic Insufficiency (EPI) in the defined German population is 6.4 cases per 100,000 inhabitants.
-
As per the study conducted by Lin Y Tamakosh et al., titled “Nationwide epidemiological survey of chronic pancreatitis in Japan” the estimated prevalence of Exocrine Pancreatic Insufficiency (EPI) in Japan is more than 25 cases per 100,000 with a higher rate in men compared to women.
-
A study conducted in 2005 by Dietrich Rothenbacher et al. represented a clear increase in Exocrine Pancreatic Insufficiency (EPI) with age, from 6.0% in the 50-54 years age group to 15.5% in the 65-69 years age group, and 13.4% in the 70-75 years age group.
-
As per Delveinsight, among the Exocrine Pancreatic Insufficiency (EPI) patients, males show a higher proportion of prevalence of EPI as compared to females in the 7MM.
Key Benefits of Exocrine Pancreatic Insufficiency (EPI) Market Report
-
Exocrine Pancreatic Insufficiency (EPI) market report provides an in-depth analysis of Exocrine Pancreatic Insufficiency (EPI) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Exocrine Pancreatic Insufficiency (EPI) market report will help in developing business strategies by understanding the Exocrine Pancreatic Insufficiency (EPI) Market trends & developments, key players, and future market competition that will shape and drive the Exocrine Pancreatic Insufficiency (EPI) market in the upcoming years.
-
The Exocrine Pancreatic Insufficiency (EPI) market report covers Exocrine Pancreatic Insufficiency (EPI) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Exocrine Pancreatic Insufficiency (EPI) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Exocrine Pancreatic Insufficiency (EPI) Market
As per the Delveinsight, the Exocrine Pancreatic Insufficiency (EPI) market size shall grow during the forecast period owing to the launch of upcoming therapies.
The Exocrine Pancreatic Insufficiency (EPI) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Exocrine Pancreatic Insufficiency (EPI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Exocrine Pancreatic Insufficiency (EPI) Epidemiology
The Exocrine Pancreatic Insufficiency (EPI) epidemiology section covers insights about the historical and current Exocrine Pancreatic Insufficiency (EPI) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Exocrine Pancreatic Insufficiency (EPI) Drugs Uptake and Key Market Players
The Exocrine Pancreatic Insufficiency (EPI) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Exocrine Pancreatic Insufficiency (EPI) market or expected to get launched in the market during the study period. The analysis covers Exocrine Pancreatic Insufficiency (EPI) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The diagnosis, prognosis, and management of Exocrine Pancreatic Insufficiency continue to be challenging in current practice. This is related to an incomplete understanding of the pathophysiology of the disease and its associated disorders and the complexity of initiating factors. However, the companies are currently working on novel therapies for the effective management of Exocrine Pancreatic Insufficiency (EPI).
Exocrine Pancreatic Insufficiency (EPI) companies involved in therapeutics development include:
Repha GmbH
Adare Pharmaceuticals
Janssen Pharmaceuticals
Solvay Pharmaceuticals
Synspira Therapeutics
AzurRx Biopharma
And many others
Exocrine Pancreatic Insufficiency (EPI) therapies covered in the report include:
MS1819
SNSP003
Creon
Pancreaze
Zenpep
Nortase
And many more
Table of Content
1. Key Insights
2. Executive Summary
3. Exocrine Pancreatic Insufficiency (EPI) Competitive Intelligence Analysis
4. Exocrine Pancreatic Insufficiency (EPI) Market Overview at a Glance
5. Exocrine Pancreatic Insufficiency (EPI) Disease Background and Overview
6. Exocrine Pancreatic Insufficiency (EPI) Patient Journey
7. Exocrine Pancreatic Insufficiency (EPI) Epidemiology and Patient Population
8. Exocrine Pancreatic Insufficiency (EPI) Treatment Algorithm, Current Treatment, and Medical Practices
9. Exocrine Pancreatic Insufficiency (EPI) Unmet Needs
10. Key Endpoints of Exocrine Pancreatic Insufficiency (EPI) Treatment
11. Exocrine Pancreatic Insufficiency (EPI) Marketed Products
12. Exocrine Pancreatic Insufficiency (EPI) Emerging Therapies
13. Exocrine Pancreatic Insufficiency (EPI) Seven Major Market Analysis
14. Attribute Analysis
15. Exocrine Pancreatic Insufficiency (EPI) Market Outlook (7 major markets)
16. Exocrine Pancreatic Insufficiency (EPI) Access and Reimbursement Overview
17. KOL Views on the Exocrine Pancreatic Insufficiency (EPI) Market.
18. Exocrine Pancreatic Insufficiency (EPI) Market Drivers
19. Exocrine Pancreatic Insufficiency (EPI) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Related Reports
Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast
DelveInsight’s Exocrine Pancreatic Insufficiency – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of EPI in the 7MM.
Exocrine Pancreatic Insufficiency (EPI) Pipeline Insights
Exocrine Pancreatic Insufficiency (EPI) Pipeline Insight, 2020 report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Exocrine Pancreatic Insufficiency (EPI) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/